PHGDH amplification and altered glucose metabolism in human melanoma

Pigment Cell and Melanoma Research

Volumn 24, Issue 6, 2011, Pages 1112-1115

  Mullarky, Edouard ^a   Mattaini, Katherine R ^b   Vander Heiden, Matthew G ^a,b   Cantley, Lewis C ^a   Locasale, Jason W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

3 phosphoglycerate; Biosynthesis; Cancer; Glycolysis; Metabolism; PHGDH; Serine

Indexed keywords

GLUCOSE; PHOSPHOGLYCERATE DEHYDROGENASE;

BIOMASS; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GLUCOSE METABOLISM; HUMAN; MELANOMA; NOTE; ONCOGENE;

GENE AMPLIFICATION; GLUCOSE; HUMANS; MELANOMA; METABOLIC NETWORKS AND PATHWAYS; PHOSPHOGLYCERATE DEHYDROGENASE; SKIN NEOPLASMS;

EID: 81955167417     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00919.x     Document Type: Note

References (32)

1. Beroukhim, R., Mermel, C.H., Porter, D. et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905.
2. Cheong, H., Lindsten, T., Wu, J., Lu, C., and Thompson, C.B. (2011). Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. Proc. Natl Acad. Sci. USA 108, 11121-11126.
3. Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233.
4. Dang, L., White, D.W., Gross, S. et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.
5. De Koning, T.J., Snell, K., Duran, M., Berger, R., Poll-The, B.T., and Surtees, R. (2003). L-serine in disease and development. Biochem. J. 371, 653-661.
6. Deberardinis, R.J., and Cheng, T. (2010). Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324.
7. Deberardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008a). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20.
8. Deberardinis, R.J., Sayed, N., Ditsworth, D., and Thompson, C.B. (2008b). Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54-61.
9. Debnath, J., and Brugge, J.S. (2005). Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5, 675-688.
10. Debnath, J., Muthuswamy, S.K., and Brugge, J.S. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268.
11. Eng, C.H., Yu, K., Lucas, J., White, E., and Abraham, R.T. (2010). Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal. 3, ra31.
12. Figueroa, M.E., Abdel-Wahab, O., Lu, C. et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567.
13. Futerman, A.H., and Riezman, H. (2005). The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15, 312-318.
14. Hao, H.X., Khalimonchuk, O., Schraders, M. et al. (2009). SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139-1142.
15. Ko, M., Huang, Y., Jankowska, A.M. et al. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843.
16. Ko, M., Bandukwala, H.S., An, J., Lamperti, E.D., Thompson, E.C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S.B., and Rao, A. (2011). Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl Acad. Sci. USA 108, 14566-14571.
17. Kuge, O., and Nishijima, M. (2003). Biosynthetic regulation and intracellular transport of phosphatidylserine in mammalian cells. J. Biochem. 133, 397-403.
18. Locasale, J.W., Cantley, L.C., and Vander Heiden, M.G. (2009). Cancer's insatiable appetite. Nat. Biotechnol. 27, 916-917.
19. Locasale, J.W., Grassian, A.R., Melman, T. et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869-874.
20. Mardis, E.R., Ding, L., Dooling, D.J. et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066.
21. Moran-Crusio, K., Reavie, L., Shih, A. et al. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24.
22. Pind, S., Slominski, E., Mauthe, J., Pearlman, K., Swoboda, K.J., Wilkins, J.A., Sauder, P., and Natowicz, M.R. (2002). V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme. J. Biol. Chem. 277, 7136-7143.
23. Pollard, P.J., Wortham, N.C., and Tomlinson, I.P. (2003). The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann. Med. 35, 632-639.
24. Possemato, R., Marks, K.M., Shaul, D.Y. et al. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350.
25. Snell, K. (1984). Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Adv. Enzyme Regul. 22, 325-400.
26. Snell, K. (1986). The duality of pathways for serine biosynthesis is a fallacy. Trends Biochem. Sci. 11, 241-243.
27. Thompson, C.B. (2009). Metabolic enzymes as oncogenes or tumor suppressors. N. Engl. J. Med. 360, 813-815.
28. Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
29. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
30. Warburg, O., Posener, K., and Negelein, E. (1924). Ueber den Stoffwechsel der Tumoren. Biochem. Z. 152, 319-344.
31. Xu, W., Yang, H., Liu, Y. et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30.
32. Yen, K.E., Bittinger, M.A., Su, S.M., and Fantin, V.R. (2010). Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29, 6409-6417.